A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.
In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:ABBVIE CALL CENTER
- 電話番号:844-663-3742
- メール:abbvieclinicaltrials@abbvie.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope National Medical Center /ID# 281381
-
Irvine、California、アメリカ、92618
- 募集
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Sarah Cannon Research Institute at HealthONE /ID# 278785
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago Medical Center /ID# 278295
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- 募集
- University Of Nebraska Medical Center /ID# 281020
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- NEXT Oncology - San Antonio /ID# 278606
-
-
Utah
-
West Valley City、Utah、アメリカ、84119
- 募集
- Start Mountain Region /ID# 278609
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Next Virginia /ID# 278607
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus /ID# 278418
-
Jerusalem、イスラエル、91120
- 募集
- Hadassah Medical Center-Hebrew University /ID# 278420
-
-
Tel Aviv
-
Ramat Gan、Tel Aviv、イスラエル、5265601
- 募集
- The Chaim Sheba Medical Center /ID# 278416
-
-
-
-
New South Wales
-
Blacktown、New South Wales、オーストラリア、2148
- 募集
- Blacktown Hospital /ID# 282426
-
-
Victoria
-
Clayton、Victoria、オーストラリア、3168
- 募集
- Monash Health - Monash Medical Centre - Clayton /ID# 281468
-
Melbourne、Victoria、オーストラリア、3000
- 募集
- Peter MacCallum Cancer Centre. /ID# 281751
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall d Hebron /ID# 280442
-
Madrid、スペイン、28040
- 募集
- Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
-
Madrid、スペイン、28050
- 募集
- Hospital Universitario HM Sanchinarro /ID# 280439
-
-
Madrid
-
Majadahonda、Madrid、スペイン、28222
- 募集
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
-
-
-
-
Pays de la Loire Region
-
Saint-Herblain、Pays de la Loire Region、フランス、44805
- 募集
- Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
-
-
Rhone
-
Lyon、Rhone、フランス、69373
- 募集
- Centre Leon Berard /ID# 280575
-
-
-
-
-
Lisbon、ポルトガル、1649-035
- 募集
- Unidade Local de Saude de Santa Maria /ID# 280296
-
Porto、ポルトガル、4200-072
- 募集
- Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
-
-
-
-
-
Taipei、台湾、112
- 募集
- Taipei Veterans General Hospital /ID# 281349
-
Taipei、台湾、100
- 募集
- National Taiwan University Hospital /ID# 280701
-
-
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- 募集
- National Cancer Center Hospital East /ID# 278604
-
-
Saitama
-
Hidaka、Saitama、日本、350-1298
- 募集
- Saitama Medical University International Medical Center /ID# 278437
-
-
Shizuoka
-
Sunto-gun、Shizuoka、日本、411-8777
- 募集
- Shizuoka Cancer Center /ID# 278538
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
- Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
For Parts 1-4:
- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).
For Parts 5-6:
- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
Exclusion Criteria:
- Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
- Participants with platinum refractory disease.
- Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
- Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
- Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
For Parts 3-6:
- History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
- History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
- Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.
For Parts 5-6:
- Participants who had prior allergic reaction to platinum containing compound.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1: ABBV-901 Dose Escalation
Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
実験的:Part 2: ABBV-901 Optimization Dose A
Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
実験的:Part 2: ABBV-901 Optimization Dose B
Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
実験的:Part 2: ABBV-901 Optimization Dose C
Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
実験的:Part 3: ABBV-901 + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
実験的:Part 4: ABBV-901 + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
実験的:Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
|
実験的:Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
時間枠:Up to Approximately 3 Years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 3 Years
|
|
Overall Response (as assessed by the investigator)
時間枠:Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator. |
Up to Approximately 3 Years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response (as assessed by independent central review)
時間枠:Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR). |
Up to Approximately 3 Years
|
|
Duration of Response (DOR)
時間枠:Up to Approximately 3 Years
|
DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Progression-free survival (PFS)
時間枠:Up to Approximately 3 Years
|
PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
時間枠:Up to Approximately 3 Years
|
OS is defined as time from first study treatment to death due to any cause. |
Up to Approximately 3 Years
|
|
Disease Control Rate
時間枠:Up to Approximately 3 Years
|
Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria. |
Up to Approximately 3 Years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- M25-760
- 2025-522209-40-00 (Ctis)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。